Global Amlodipine Besylate Market Size, Share and Trends Analysis Report, By Type (2.5mg Tablets, 5mg Tablets, and 10mg Tablets), By Application (High Blood Pressure, and Heart Diseases) Forecast (2022-2028)

The global amlodipine besylate market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Amlodipine is a drug used to treat blood pressure, which can be taken with or without other medications. Various chronic diseases including heart attacks, strokes, and kidney-related diseases can also be prevented by decreasing the blood pressure. Amlodipine relaxes the blood arteries, further allowing blood to flow more easily. Thus, the increasing incidence of heart diseases across the globe owing to the changing lifestyles & eating habits of the population and rise in prevalence of diabetes and obesity across the globe, wi directly fuels the demand of the amlodipine besylate market. Accordig to the Government of Canada, in 2021, approximately 2.4 million that is one in twelve Canadian adults aged 20 and above have been diagnosed with heart disease. Moreover, every hour, about 12 Canadian adults aged 20 and above are estimated to die due to diagnosed heart disease.

 

Another factor driving the demand of amlodipine besylate drug is the growing launch of new product and treatment among the maret catering to control high blood pressure and heart attacks across the globe. For instance, in May 2020, Kitov Pharma Ltd. developed Consensi, which is a combination of celecoxib and amlodipine besylate to treat hypertension. In addition, Burke Therapeutics, a marketing partner of Kitov’s US distributor, and Coeptis Pharmaceuticals are selling Consensi across the US. In February 2022, the US Food and Drug Administration (USFDA) approved Norliqva (amlodipine) oral solution for the treatment of hypertension particularly in children 6 years and older and in adults to lower blood pressure. Additionally, In November 2021, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has granted pharma major Torrent Pharmaceuticals Ltd. the supplementary strength of fixed-dose combination drug Amlodipine Besylate USP eq. to Amlodipine 10mg plus Olmesartan Medoxomil USP 40mg Tablet, approving the waiver of phase 3 clinical trial.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

· Competitive Landscape– Pfizer Inc., Mylan N.V., Dr. Reddy’s Laboratories, Apotex Inc., Teva Pharmaceutical Industries Ltd., among others.

 

 

Key questions addressed by the report

 

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Amlodipine Besylate Market Report by Segment

 

By Type

• 5mg Tablets
• 5mg Tablets
• 10mg Tablets

By Application

• High Blood Pressure
• Heart Diseases

 

Global Amlodipine Besylate Market Report by Region

 

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa